ReviewClinical, cosmetic and investigational dermatology2019
Telogen effluvium: a comprehensive review.
Review in Clinical, cosmetic and investigational dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Adenosine as an Active Ingredient in Topical Preparations Against Hair Loss: A Systematic Review and Meta-Analysis of Published Clinical Trials.Biomolecules · 2025Pooled it
- The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?American journal of clinical dermatology · 2026Review
- Exploring the Potential Links between Telogen Effluvium, Alopecia Areata, Pressure-Induced Alopecia, and General Anesthesia: A Narrative Review.Dermatology and therapy · 2026Review
- Automated Quantification of Shedding Hairs from Smartphone Photographs Using an AI Tool for Alopecia Monitoring.Clinical, cosmetic and investigational dermatology · 2026Article
- From a stem-cell-centered to a niche-centered view: the core role of collagen networks in hair loss and hair follicle miniaturization.Frontiers in cell and developmental biology · 2026Review
- Efficacy and Safety of a Drinkable Nutraceutical in Premenopausal Women with Telogen Effluvium: A 6-Month, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study.Dermatology and therapy · 2026Article
- A Novel, Drinkable Food Supplement Formulation Reduces Hair Shedding and Increases the Percentage of Anagen Scalp Hair Follicles in Females with Hair Loss.Journal of clinical medicine · 2025Article
- Ex vivo detection of SARS CoV 2 spike protein in human hair follicles and potential link to telogen effluvium.Scientific reports · 2025Article
- Pea Sprout Extract Promotes Hair Follicle Regeneration via Anagen Phase Prolongation and Dual Modulation of Oxidative and Inflammatory Signaling.Journal of microbiology and biotechnology · 2025Article
- Post-COVID Hair Loss in the Indian Subcontinent: Clinical Patterns and Association with Disease Severity.Dermatology practical & conceptual · 2025Article
- Article
- Alopecia Areata Incognita: Current Evidence.Dermatology and therapy · 2025Review
- A Well-Tolerated Hair Serum Containing New Natural Active Ingredients Reduced Hair Loss and Improved Quality of Life in Women With Chronic Telogen Effluvium: A 16-Week Controlled Study.Journal of cosmetic dermatology · 2024Article
- Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia.Life (Basel, Switzerland) · 2024Review
- Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management.Journal of clinical medicine · 2024Article
- CBD: A Potential Lead against Hair Loss, Alopecia, and its Potential Mechanisms.Current drug discovery technologies · 2024Review
- COVID-19-induced hair shedding and related risk factors: A Saudi perspective.Journal of family medicine and primary care · 2023Article
- Effect of topical naringenin and its combination with minoxidil on enhancing hair growth in a mouse model.Journal of medicine and life · 2023Article
- Alopecias: Practical Tips for the Management of Biopsies and Main Diagnostic Clues for General Pathologists and Dermatopathologists.Journal of clinical medicine · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive hair shedding is a common and alarming phenomenon, usually complained about by women. The disorder, named telogen effluvium (TE), bears several problems which are discussed in this essay. They are as follows: 1) how profuse a hair loss must be for TE to be diagnosed; 2) its heterogeneity that needs to be properly classified; 3) its distinction from androgenetic alopecia (AGA) with which it is often associated; 4) its main symptom, trichodynia, which is unclear how frequent and how diagnostic could be; 5) why histopathology has been reported to be nonspecific; and 6) its management, from diagnosis to treatment. A common mistake of the dermatologist is to minimize the complaint. Instead, the disorder may have a profound impact on the patients' mind and would require attention, time, and empathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.